A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects

ObjectiveThis study was conducted to explore the tolerance, variability, pharmacokinetics (PK), and pharmacodynamics (PD) of denosumab biosimilar (QL1206) in healthy Chinese subjects.MethodsThis is a randomized, double-blind, two-arm, parallel study performed to examine the bioequivalence of denosum...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Hong Zhang, Min Wu, Xiaoxue Zhu, Cuiyun Li, Xiaojiao Li, Jixuan Sun, Chengjiao Liu, Quan Liu, Wei Wei, Junqi Niu, Yanhua Ding
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2020-10-01
Σειρά:	Frontiers in Pharmacology
Θέματα:	denosumab biosimilar immunogenicity pharmacokinetics pharmacodynamics inter-subject variability
Διαθέσιμο Online:	https://www.frontiersin.org/article/10.3389/fphar.2020.01329/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!